EVONIK INDUST.(U.ARD)2 (EVKA) - Net Assets
Based on the latest financial reports, EVONIK INDUST.(U.ARD)2 (EVKA) has net assets worth €8.17 Billion EUR (≈ $9.56 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€17.98 Billion ≈ $21.02 Billion USD) and total liabilities (€9.81 Billion ≈ $11.47 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check EVONIK INDUST.(U.ARD)2 liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €8.17 Billion |
| % of Total Assets | 45.46% |
| Annual Growth Rate | -3.36% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 13.74 |
EVONIK INDUST.(U.ARD)2 - Net Assets Trend (2021–2025)
This chart illustrates how EVONIK INDUST.(U.ARD)2's net assets have evolved over time, based on quarterly financial data. Also explore total assets of EVONIK INDUST.(U.ARD)2 for the complete picture of this company's asset base.
Annual Net Assets for EVONIK INDUST.(U.ARD)2 (2021–2025)
The table below shows the annual net assets of EVONIK INDUST.(U.ARD)2 from 2021 to 2025. For live valuation and market cap data, see EVONIK INDUST.(U.ARD)2 (EVKA) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €8.17 Billion ≈ $9.56 Billion |
-10.18% |
| 2024-12-31 | €9.10 Billion ≈ $10.64 Billion |
+1.27% |
| 2023-12-31 | €8.99 Billion ≈ $10.51 Billion |
-18.72% |
| 2022-12-31 | €11.06 Billion ≈ $12.93 Billion |
+17.97% |
| 2021-12-31 | €9.37 Billion ≈ $10.96 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to EVONIK INDUST.(U.ARD)2's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7.6% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €7.17 Billion | 88.45% |
| Other Components | €937.00 Million | 11.55% |
| Total Equity | €8.11 Billion | 100.00% |
EVONIK INDUST.(U.ARD)2 Competitors by Market Cap
The table below lists competitors of EVONIK INDUST.(U.ARD)2 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
IDACORP Inc
NYSE:IDA
|
$7.41 Billion |
|
Sunwoda Electronic
SHE:300207
|
$7.42 Billion |
|
Brown-Forman Corporation
NYSE:BF-B
|
$7.42 Billion |
|
Medibank Private Limited
F:MPV
|
$7.42 Billion |
|
Symbotic Inc
NASDAQ:SYM
|
$7.41 Billion |
|
HYBE Co. Ltd
KO:352820
|
$7.40 Billion |
|
Qorvo Inc
NASDAQ:QRVO
|
$7.40 Billion |
|
Molson Coors Brewing Co Class B
NYSE:TAP
|
$7.40 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in EVONIK INDUST.(U.ARD)2's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 9,020,000,000 to 8,110,000,000, a change of -910,000,000 (-10.1%).
- Net income of 265,000,000 contributed positively to equity growth.
- Dividend payments of 545,000,000 reduced retained earnings.
- Share repurchases of 1,000,000 reduced equity.
- New share issuances of 1,000,000 increased equity.
- Other factors decreased equity by 630,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €265.00 Million | +3.27% |
| Dividends Paid | €545.00 Million | -6.72% |
| Share Repurchases | €1.00 Million | -0.01% |
| Share Issuances | €1.00 Million | +0.01% |
| Other Changes | €-630.00 Million | -7.77% |
| Total Change | €- | -10.09% |
Book Value vs Market Value Analysis
This analysis compares EVONIK INDUST.(U.ARD)2's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.48x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €19.93 | €8.35 | x |
| 2022-12-31 | €23.55 | €8.35 | x |
| 2023-12-31 | €19.12 | €8.35 | x |
| 2024-12-31 | €19.36 | €8.35 | x |
| 2025-12-31 | €17.40 | €8.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently EVONIK INDUST.(U.ARD)2 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.27%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.88%
- • Asset Turnover: 0.78x
- • Equity Multiplier: 2.22x
- Recent ROE (3.27%) is above the historical average (2.69%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 8.03% | 4.99% | 0.67x | 2.40x | €-182.90 Million |
| 2022 | 4.92% | 2.92% | 0.85x | 1.99x | €-557.40 Million |
| 2023 | -5.22% | -3.05% | 0.77x | 2.24x | €-1.36 Billion |
| 2024 | 2.46% | 1.46% | 0.77x | 2.19x | €-680.00 Million |
| 2025 | 3.27% | 1.88% | 0.78x | 2.22x | €-546.00 Million |
Industry Comparison
This section compares EVONIK INDUST.(U.ARD)2's net assets metrics with peer companies in the Specialty Chemicals industry.
Industry Context
- Industry: Specialty Chemicals
- Average net assets among peers: $3,071,504,005
- Average return on equity (ROE) among peers: -30.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| EVONIK INDUST.(U.ARD)2 (EVKA) | €8.17 Billion | 8.03% | 1.20x | $7.41 Billion |
| GRAPHENE MANUFACT.GROUP (0GF) | $10.10 Million | -116.54% | 0.65x | $152.93 Million |
| Orion Engineered Carbons SA (0OE) | $478.50 Million | 21.63% | 2.83x | $318.41 Million |
| H&R GmbH & Co. KGaA (2HRA) | $189.16 Million | -7.42% | 2.14x | $183.88 Million |
| Dotz Nano Ltd (57N) | $3.79 Million | -160.22% | 0.25x | $3.81 Million |
| EXPLOS. PROD. CHIM.EO 31 (9Z50) | $106.13 Million | 5.52% | 2.43x | $536.15 Million |
| Altech Chemicals Ltd (A3Y) | $20.44 Million | -57.36% | 0.80x | $27.76 Million |
| AlzChem Group AG (ACT) | $0.00 | 0.00% | 0.00x | $1.83 Billion |
| AIR LIQUIDE ADR 1/5/EO 11 (AILA) | $25.04 Billion | 12.29% | 0.93x | $103.86 Billion |
| AKZO NOBEL SPONS.ADRS 1/3 (AKUP) | $4.82 Billion | 13.17% | 1.89x | $8.57 Billion |
| BRAIN Biotech AG (BNN) | $41.83 Million | -11.89% | 0.86x | $51.56 Million |
About EVONIK INDUST.(U.ARD)2
Evonik Industries AG operates as a chemicals company in the Asia-Pacific, Europe, the Middle East, Africa, and the Americas. It operates through the Advanced Technologies, Custom Solutions, and Infrastructure segments. The Advanced Technologies segment provides polymers for medical applications; crosslinkers; hydrogen peroxide, a sterilizing agent for cleaning silicon wafers and a bleaching agent… Read more